CoChat
Sign Up
Cited by 256

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure

Zeisel, Mirjam B, Lucifora, Julie, Mason, William S, Sureau, Camille, Beck, Jürgen, Levrero, Massimo, Kann, Michael, Knolle, Percy A, Benkirane, Monsef, Durantel, David, Michel, Marie-Louise, Autran, Brigitte, Cosset, François-Loïc, Strick-Marchand, Hélène, Trépo, Christian, Kao, Jia-Horng, Carrat, Fabrice, Lacombe, Karine, Schinazi, Raymond F, Barré-Sinoussi, Françoise, Delfraissy, Jean-François, Zoulim, Fabien·2015·Gut
DOI 10.1136/gutjnl-2014-308943
Open this paper in CoChat — free account

Abstract

HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis ‘HBV Cure’ programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2014-308943

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cas9 has been used to target conserved regions of HBV responsible for virus persistence and replication and not directly targeted by current anti-viral therapies.

    “Cas9 has been used to target conserved regions of the hepatitis B virus (HBV), which are responsible for virus persistence and replication and are not directly targeted by current anti-viral therapies [169].”

    From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [169]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 169

  1. 10.1016/S0140-6736(05)17701-0 · DOI
  2. 10.1056/NEJMoa043470 · DOI
  3. 10.1056/NEJMoa066422 · DOI
  4. 10.1056/NEJMoa051285 · DOI
  5. 10.1016/S0140-6736(14)60220-8 · DOI
  6. 10.1016/j.jhep.2014.05.016 · DOI
  7. 10.1038/nri3262 · DOI
  8. Yang, 1995, Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination, J Virol, 69, 4029, 10.1128/jvi.69.7.4029-4036.1995 · DOI
  9. Hino, 1989, Features of two hepatitis B virus (HBV) DNA integrations suggest mechanisms of HBV integration, J Virol, 63, 2638, 10.1128/jvi.63.6.2638-2643.1989 · DOI
  10. 10.1007/978-3-642-38965-8_4 · DOI
  11. 10.1172/JCI8098 · DOI
  12. 10.1002/hep.22386 · DOI
  13. Seeger C , Zoulim F , Mason W . Molecular Biology of hepatitis B viruses. In: Howley P , Knipe D , eds. Fields virology. Lippincott: Williams and Wilkins, 2013:2185 2221.
  14. 10.1016/j.vaccine.2004.10.045 · DOI
  15. 10.1016/j.jhep.2012.02.010 · DOI
  16. 10.1093/infdis/jis569 · DOI
  17. Bertoletti A , Kennedy PT . The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol Published Online First: 1 Sept 2014. doi: 10.1038/cmi.2014.79 · DOI
  18. 10.1053/j.gastro.2012.06.009 · DOI
  19. 10.1038/nri2075 · DOI
  20. Lan, 2013, Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance, Hepatology, 58, 73, 10.1002/hep.26339 · DOI
  21. 10.1002/hep.24500 · DOI
  22. 10.1016/S1473-3099(02)00315-8 · DOI
  23. 10.1056/NEJM199706263362602 · DOI · Paper page
  24. 10.1093/jnci/djp288 · DOI
  25. 10.1053/j.gastro.2012.02.007 · DOI
  26. 10.1001/jama.295.1.65 · DOI · Paper page
  27. 10.1053/j.gastro.2005.11.016 · DOI
  28. 10.1053/j.gastro.2011.04.046 · DOI
  29. 10.1093/infdis/jir687 · DOI
  30. 10.1136/gutjnl-2014-306977 · DOI
  31. 10.1111/jgh.12010 · DOI
  32. 10.1016/S1470-2045(11)70077-8 · DOI
  33. Arends P , Sonneveld MJ , Zoutendijk R , et al . Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2014. · DOI
  34. 10.1053/j.gastro.2010.01.042 · DOI
  35. 10.1016/j.antiviral.2012.09.006 · DOI
  36. 10.1002/hep.510250141 · DOI
  37. 10.1053/j.gastro.2008.07.008 · DOI
  38. 10.1002/hep.22945 · DOI
  39. 10.1053/j.gastro.2009.01.052 · DOI
  40. 10.1038/nrgastro.2009.205 · DOI
  41. 10.1136/gutjnl-2012-302056 · DOI
  42. Gripon, 1988, Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide, J Virol, 62, 4136, 10.1128/jvi.62.11.4136-4143.1988 · DOI
  43. 10.1034/j.1600-0684.2003.00022.x · DOI
  44. von Weizsacker, 2004, The tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary tupaia hepatocytes, Methods Mol Med, 96, 153
  45. 10.1073/pnas.232137699 · DOI
  46. 10.7554/eLife.00049 · DOI
  47. 10.1053/j.gastro.2013.12.024 · DOI
  48. 10.1073/pnas.1412631111 · DOI
  49. 10.1126/science.284.5415.825 · DOI · Paper page
  50. 10.1073/pnas.0401771101 · DOI
  51. Harrington, 2012, State of the (research) chimp, Lab Anim, 41, 31
  52. 10.1002/hep.26428 · DOI
  53. 10.1128/JVI.03540-12 · DOI
  54. 10.1016/j.patbio.2010.04.005 · DOI
  55. 10.3109/00498254.2013.867553 · DOI
  56. 10.1053/j.gastro.2013.09.009 · DOI
  57. 10.1172/JCI40094 · DOI
  58. 10.1055/s-2006-939760 · DOI
  59. 10.1016/j.jhep.2012.12.008 · DOI
  60. 10.3851/IMP2075 · DOI
  61. 10.1371/journal.pone.0025096 · DOI
  62. 10.1016/j.antiviral.2008.07.006 · DOI
  63. 10.1016/j.jhep.2013.11.010 · DOI
  64. 10.1002/hep.24758 · DOI
  65. 10.1053/j.gastro.2012.03.006 · DOI
  66. 10.1128/JVI.03134-12 · DOI
  67. 10.1016/0042-6822(92)90559-8 · DOI
  68. Sureau, 1994, The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus, J Virol, 68, 4063, 10.1128/jvi.68.6.4063-4066.1994 · DOI
  69. 10.1128/JVI.77.9.5519-5523.2003 · DOI
  70. 10.1128/JVI.00096-07 · DOI
  71. 10.1128/JVI.02528-09 · DOI
  72. 10.1128/JVI.79.16.10460-10466.2005 · DOI
  73. 10.1128/JVI.01594-09 · DOI
  74. 10.1002/hep.21896 · DOI
  75. 10.1128/JVI.00678-09 · DOI
  76. 10.1128/JVI.01026-09 · DOI
  77. 10.1111/j.1462-5822.2008.01250.x · DOI
  78. 10.1128/JVI.79.3.1613-1622.2005 · DOI
  79. 10.1038/nbt1389 · DOI
  80. 10.1128/JVI.03478-13 · DOI
  81. 10.1053/j.gastro.2014.04.030 · DOI
  82. 10.1128/JVI.00873-12 · DOI
  83. 10.1128/JVI.01207-09 · DOI
  84. 10.1128/JVI.02303-05 · DOI
  85. 10.1371/journal.ppat.1000741 · DOI
  86. 10.1073/pnas.1409986111 · DOI
  87. 10.1007/BF01703079 · DOI
  88. 10.1006/jmbi.2000.4481 · DOI
  89. 10.1053/j.gastro.2006.01.001 · DOI
  90. 10.1073/pnas.0908365106 · DOI
  91. 10.1016/j.jhep.2011.02.015 · DOI
  92. 10.1073/pnas.0704000104 · DOI
  93. 10.1016/j.jhep.2010.10.005 · DOI · Paper page
  94. 10.1038/nri3169 · DOI
  95. 10.1038/nri1573 · DOI
  96. 10.3851/IMP1620 · DOI
  97. 10.1128/JVI.01844-08 · DOI
  98. 10.1136/gut.2008.163600 · DOI
  99. 10.1002/hep.23226 · DOI
  100. 10.1002/hep.23230 · DOI
  101. 10.3390/v2071394 · DOI
  102. Zannetti, 2013, HBV inhibits the Aim-2 INFLAMMASOME in human KUPFFER cells, J Hepatol, 58, S140, 10.1016/S0168-8278(13)60337-2 · DOI
  103. Gruffaz, 2013, The nuclear function of Hepatitis B capsid (HBc) protein is to inhibit IFN response very early after infection of hepatocytes, Hepatology, 58, 276A
  104. 10.1002/hep.26668 · DOI · Paper page
  105. 10.1371/journal.pone.0026315 · DOI
  106. 10.1371/journal.pone.0015324 · DOI
  107. 10.1053/j.gastro.2012.08.046 · DOI
  108. 10.1002/hep.21482 · DOI
  109. 10.1002/hep.26062 · DOI
  110. 10.1016/j.coviro.2013.08.004 · DOI
  111. 10.1097/COH.0b013e328345a328 · DOI
  112. 10.1097/QAD.0000000000000295 · DOI
  113. 10.3748/wjg.v20.i24.7707 · DOI
  114. 10.1517/14728214.2011.646260 · DOI
  115. 10.1053/j.gastro.2009.08.063 · DOI
  116. 10.1016/S0168-8278(12)60012-9 · DOI
  117. King, 1998, Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2′,3′-dideoxy-3′-thiacytidine, Antimicrob Agents Chemother, 42, 3179, 10.1128/AAC.42.12.3179 · DOI
  118. 10.1016/j.antiviral.2007.06.014 · DOI
  119. 10.1128/AAC.46.9.3057-3060.2002 · DOI
  120. 10.1016/j.antiviral.2011.08.012 · DOI
  121. 10.1016/S0166-3542(01)00216-9 · DOI
  122. 10.1126/science.1077215 · DOI
  123. 10.1179/joc.2008.20.4.458 · DOI
  124. 10.1073/pnas.0409732102 · DOI
  125. 10.1002/jmr.801 · DOI
  126. 10.3851/IMP2152 · DOI
  127. 10.1002/rcm.6710 · DOI
  128. 10.1099/vir.0.18966-0 · DOI
  129. Twu, 1989, Transcription of the human beta interferon gene is inhibited by hepatitis B virus, J Virol, 63, 3065, 10.1128/jvi.63.7.3065-3071.1989 · DOI
  130. Belloni, 2013, HAPs hepatitis B virus (HBV) capsid inhibitors block core protein interaction with the viral minichromosome and host cell genes and affect cccDNA transcription and sta- bility, Hepatology, 54, 277A
  131. 10.1128/AAC.00473-12 · DOI
  132. 10.1038/mt.2013.212 · DOI · Paper page
  133. 10.1038/mt.2013.170 · DOI · Paper page
  134. 10.1371/journal.pone.0097579 · DOI
  135. 10.1128/JVI.00052-12 · DOI
  136. 10.1172/JCI58847 · DOI
  137. Belloni, 2012, Mimicking Interferon-α (IFNα) inhibitory activity on hep- atitis B virus (HBV) transcription and replication by tar- geting the epigenetic control of nuclear cccDNA minichromosome with epigenetic small molecules, Hepatology, 56, 369A
  138. 10.1038/mt.2013.31 · DOI
  139. 10.1053/j.gastro.2011.05.001 · DOI
  140. 10.1159/000360938 · DOI
  141. 10.1016/j.jhep.2012.09.022 · DOI
  142. Durantel, 2007, Glucosidase inhibitors as antiviral agents for hepatitis B and C, Curr Opin Investig Drugs, 8, 125
  143. 10.1016/j.antiviral.2012.12.008 · DOI
  144. 10.1016/j.jhep.2013.11.022 · DOI
  145. 10.1016/j.antiviral.2014.03.017 · DOI
  146. 10.5483/BMBRep.2008.41.9.640 · DOI
  147. 10.1021/jm200696v · DOI
  148. 10.1016/j.antiviral.2014.04.002 · DOI
  149. Mahtab, 2011, REP 9 AC: a potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection, Hepatology, 54, 478A
  150. 10.1126/science.1243462 · DOI
  151. 10.1124/jpet.113.207878 · DOI
  152. 10.1111/j.1365-2893.1996.tb00094.x · DOI
  153. 10.1517/14712590902911412 · DOI
  154. 10.1016/j.antiviral.2007.08.005 · DOI
  155. 10.1021/jm200153p · DOI
  156. 10.1371/journal.pone.0101904 · DOI
  157. 10.1016/j.vaccine.2014.07.027 · DOI
  158. Yoon SK , Seo YB , Im SJ , et al . Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int Published Online First: 13 Mar 2014. doi: 10.1111/liv.12530 · DOI
  159. 10.1038/mt.2013.274 · DOI
  160. 10.1016/j.jhep.2010.12.031 · DOI
  161. 10.1136/gutjnl-2013-305707 · DOI
  162. 10.1371/journal.ppat.1003391 · DOI
  163. Al-Mahtab, 2013, A phase III clinical trial with a nasal vaccine containing both HBsAg and HBcAg in patients with chronic Hepatitis B, J Hepatol, 58, S229
  164. Martin PDC , Jacquier E , Dion S , et al . TG1050, an immunotherapeutic to treat hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut Published Online First: 26 Nov 2014. doi:10.1136/gutjnl-2014-308041 · DOI
  165. 10.1056/NEJMp1400986 · DOI
  166. Billioud, 2014, In vivo inhibition of HBV antigenemia and viremia by antisense oligonucleotides, J Hepatol, 60, S1, 10.1016/S0168-8278(14)60121-5 · DOI
  167. 10.1007/978-1-4939-1538-5_10 · DOI
  168. 10.1371/journal.ppat.1003856 · DOI
  169. 10.1016/j.jhep.2014.07.005 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zeisel, M. B., Lucifora, J., Mason, W. S., Sureau, C., Beck, J., Levrero, M., Kann, M., Knolle, P. A., Benkirane, M., Durantel, D., Michel, M.-L., Autran, B., Cosset, F.-L., Strick-Marchand, H., Trépo, C., Kao, J.-H., Carrat, F., Lacombe, K., Schinazi, R. F., Barré-Sinoussi, F., Delfraissy, J.-F., & Zoulim, F.
Affiliations
  • Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
  • Inserm U1052, CNRS UMR 5286, Cancer Research Center of Lyon (CRCL), Université de Lyon (UCBL), Lyon, France
  • Fox Chase Cancer Center, Philadelphia, USA
  • INTS, Laboratoire de Virologie Moléculaire, Paris, France
  • Department of Internal Medicine 2/Molecular Biology, University Hospital Freiburg, Freiburg, Germany
  • Center for Life Nanosciences (CNLS)—IIT/Sapienza, Rome, Italy
  • Université de Bordeaux, Microbiologie fondamentale et Pathogénicité, UMR 5234, Bordeaux, France
  • Technische Universität München, Institut für Molekulare Immunologie, München, Germany
  • Institut de Génétique Humaine, Laboratoire de Virologie Moléculaire, CNRS UPR1142, Montpellier, France
  • Laboratoire de Pathogenèse des Virus de l'Hépatite B, Département de Virologie, Institut Pasteur, Paris, France
  • Laboratory of Immunity and Infection, Inserm U945, Paris, France
  • CIRI—International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France. Inserm, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France. CNRS, UMR5308, Lyon, France
  • Innate Immunity Unit, Institut Pasteur, Inserm U668, Paris, France
  • Department of Internal Medicine, Department of Medical Research, Graduate Institute of Clinical Medicine, and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan
  • Inserm, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
  • Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia, USA
  • Inserm and Unit of Regulation of Retroviral Infections, Department of Virology, Institut Pasteur, Paris, France
  • ANRS (France Recherche Nord & Sud Sida-HIV Hépatites), Paris, France
Venue
Gut
Publisher
BMJ
Published
2015-02-10
Volume
64
Issue
8
Pages
1314-1326
ISSN
  • 0017-5749
  • 1468-3288
DOI
10.1136/gutjnl-2014-308943
Cited by
256
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review